GLP-1 / Weight Loss

Victoza vs Ozempic: Liraglutide vs Semaglutide for Diabetes

Verdict Summary

Ozempic (semaglutide) produces greater HbA1c reduction and weight loss than Victoza (liraglutide) and requires only once-weekly dosing. Victoza has a longer track record and strong cardiovascular outcome data.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionVictozaOzempic
Active CompoundLiraglutide 1.2-1.8mgSemaglutide 0.5-1mg
DosingOnce dailyOnce weekly
Avg. Weight Loss~3-4%~5-6% (diabetes dose)
CV Outcome TrialLEADER (positive)SUSTAIN-6 (positive)

Victoza Deep Dive

Victoza (liraglutide 1.2-1.8mg) was one of the first GLP-1 agonists widely adopted. The LEADER trial demonstrated significant cardiovascular risk reduction. It requires daily injection but is well-tolerated.

Ozempic Deep Dive

Ozempic's once-weekly dosing is a major convenience advantage. The SUSTAIN-6 trial showed cardiovascular benefit, and it consistently outperforms liraglutide in efficacy comparisons.

How to Choose

Choose Victoza if…

  • Daily dosing flexibility is preferred
  • You have used Victoza successfully before
  • Victoza is better covered by your insurance

Choose Ozempic if…

  • Weekly dosing convenience is important
  • You want greater HbA1c reduction
  • Weight loss is a secondary goal

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons